Biogen agrees to acquire Apellis Pharmaceuticals for five point six billion dollars to expand immunology portfolio

Mar 31, 2026, 5:18:20 PM UTC(5 hours ago)
Impact: High
Biogen agrees to acquire Apellis Pharmaceuticals for five point six billion dollars to expand immunology portfolio

Affected Assets

  • Biogen will pay forty-one dollars per share in cash representing a premium of approximately one hundred forty percent to the previous closing price
  • The deal includes a contingent value right for shareholders tied to future sales milestones of the eye disorder drug Syfovre
  • Acquisition adds two FDA-approved medicines to Biogen's portfolio which generated six hundred eighty-nine million dollars in revenue during 2025
  • The transaction is expected to close in the second quarter of 2026 and become accretive to earnings per share starting in 2027
  • Analysts view the move as a strategic effort by Biogen to diversify beyond its slowing multiple sclerosis franchise into nephrology and rare diseases

Sources

@YahooFinanceBiogen Investor RelationsReutersCNBCBloomberg
From:@YahooFinance
$APLS skyrockets 135.66% after $BIIB agreed to buy the company for $5.6 billion. 📈 https://t.co/uTBJy1Sddz
Foxly Invest Logo
Foxly InvestAI-Powered All-in-one Investment Platform

Follow us

X.comInstagramDiscord

This information is compiled from multiple sources and does not represent the views or opinions of Foxly Invest. It does not constitute investment advice or a recommendation by Foxly Invest. Investors should carefully evaluate the risks associated with any investment product and, if necessary, consult with a professional investment advisor.

The information provided on this platform is for general informational purposes only. It is not intended to be relied upon as investment advice or a recommendation to buy or sell any security. Foxly Invest does not warrant or guarantee the accuracy, reliability, or completeness of the information.

Copyright © 2026 MacroPulse AI Limited.
Privacy Notice|Account Policy
Foxly Invest Logo

Download Our App

Stay up-to-date with the market and manage your portfolio on the go

Know More
Biogen agrees to acquire Apellis Pharmaceuticals for five point six billion dollars to expand immunology portfolio | Foxly Invest